Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds

Brain Res. 1990 Jul 9;522(2):224-6. doi: 10.1016/0006-8993(90)91464-r.

Abstract

Potassium-evoked release of cholecystokinin (CCK) from slices of caudate-putamen, hippocampus, and cerebral cortex was inhibited in a dose-related fashion by phencyclidine (PCP). In order to further examine this effect, PCP-like ligands (dexoxadrol, levoxadrol, PCMP and MK-801) as well as compounds known to interact with the sigma receptor ((+)-SKF, DTG, (+)-3-PPP, and pentazocine) were tested. While some of these compounds inhibited CCK release, their rank order potency (Dex = Lev greater than PCP = PCMP greater than DTG = MK-801 = (+)-3-PPP) differs from that of known PCP-N-methyl-D-aspartate linked effects or sigma interactions. These results suggest that the mechanism by which PCP acts to inhibit CCK release may involve a novel type of PCP interaction.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Caudate Nucleus / drug effects
  • Cerebral Cortex / drug effects
  • Cholecystokinin / metabolism*
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • In Vitro Techniques
  • Male
  • Phencyclidine / analogs & derivatives*
  • Phencyclidine / pharmacology*
  • Potassium / antagonists & inhibitors*
  • Putamen / drug effects
  • Rats
  • Rats, Inbred Strains
  • Receptors, Opioid / drug effects
  • Receptors, sigma
  • Telencephalon / drug effects*
  • Telencephalon / metabolism

Substances

  • Receptors, Opioid
  • Receptors, sigma
  • Cholecystokinin
  • Phencyclidine
  • Potassium